Eversight announced a 4-year partnership with LighTopTech that aims to improve imaging modalities for eye tissues in both clinical and research settings, Eversight stated in a press release.

As part of this partnership, Eversight will integrate LighTopTech's dual modality OCX system — combining optical coherence tomography (OCT) with optical coherence microscopy — into its research and development initiatives. According to Eversight, the advanced OCT has the potential to become a single imaging modality for detailed corneal tissue analysis.

The integration of the OCX imaging system is aimed at enhancing corneal tissue evaluations in Eversight’s eye bank operations, confirming that tissue processing meets surgeons' specifications for various cornea surgeries and detecting anomalies that may render the tissue unsuitable for transplantation. Eversight will provide data to LighTopTech to inform OCX software development that could also automate endothelial cell counting, a critical metric for eye banks, among other eye tissue measurements.

The Eversight Research & Development team will also utilize the high-resolution dual-mode OCX system to capture detailed images of both the anterior (cornea and surrounding tissues) and posterior segments (neurosensory back portion) of the eye. This will enable Eversight to provide diagnostic imaging for researchers studying retinal diseases and help better understand retinal disease to one day help patients with retinal vision loss, the company said.

The partnership is bolstered by a grant from the Michigan Foundation for Vision Awareness.